Search
Duvelisib
go.drugbank.com/drugs/DB11952ApprovedInvestigationalAll the work around duvelisib showed that this agent is a potent inhibitor of both forms.[A39025] Duvelisib was developed by Verastem, Inc and FDA approved on September 24, 2018.[L4585] … Duvelisib, also known as IPI-145 and INK-1197, is a small-molecule inhibitor of phosphoinositide-3 kinases that was designed initially to prove that simultaneous inhibition of the isoforms delta and gamma
Lutetium Lu-177 vipivotide tetraxetan
go.drugbank.com/drugs/DB16778ApprovedInvestigationalIt consists of a radionuclide, [lutetium Lu-177], linked to a moiety that binds to PSMA, a transmembrane protein that is expressed in prostate cancer. … [L43787] In December 2022, lutetium Lu-177 vipivotide tetraxetan was approved by the EMA.[L43787,L45533]
Categories: Compounds used in a research, industrial, or household settingCalcium Phosphate
go.drugbank.com/drugs/DB11348ApprovedInvestigationalCalcium phosphate is typically available as an over the counter supplement, antacid, or as an added ingredient in some toothpastes [FDA Label] [L851].
Categories: Compounds used in a research, industrial, or household settingTroglitazone
go.drugbank.com/drugs/DB00197ApprovedWithdrawnTroglitazone was withdrawn in 2000 due to risk of hepatotoxicity. It was superseded by [pioglitazone] and [rosiglitazone].
Categories: Drugs Used in DiabetesSodium lauryl sulfate
go.drugbank.com/drugs/DB00815ApprovedIt is also used in creams and pastes to properly disperse the ingredients and as research tool in protein biochemistry. SLS also has some microbicidal activity. … SLS lowers surface tension of aqueous solutions and is used as fat emulsifier, wetting agent, and detergent in cosmetics, pharmaceuticals and toothpastes.
Categories: Compounds used in a research, industrial, or household settingCorynebacterium diphtheriae
go.drugbank.com/drugs/DB09877ApprovedInvestigationalThe bacteria culture is grown in a medium and through purification, diphtheria toxin is detoxified with formaldehyde and diafiltered. … The vaccine is intramuscularly administered to provide active immunization against diphtheria in infants and children.
Mixtures: Boostrix Injektionssuspension in einer Fertigspritze, Boostrix Polio - Injektionssuspension in einer FertigspritzeDaclatasvir
go.drugbank.com/drugs/DB09102ApprovedInvestigationalWithdrawnThe same dosing regimen can be used as first-line therapy in patients with genotype 3 without cirrhosis and second-line therapy in genotype 3 patients with compensated cirrhosis. … According to 2017 American Association for the Study of Liver Diseases (AASLD), 60mg of daclatasvir is recommended with 400mg [DB08934] for genotype 1a/b patients with or without cirrhosis as second-line
Products: I-HEP CLASTAVIR 30, I-HEP CLASTAVIR 60Levoleucovorin
go.drugbank.com/drugs/DB11596ApprovedInvestigationalHowever, in order to function in this role, it must first be reduced by the enzyme dihydrofolate reductase (DHFR) into the cofactors dihydrofolate (DHF) and tetrahydrofolate (THF). … Levoleucovorin, as the product Fusilev (FDA), has an additional indication for use in combination chemotherapy with 5-fluorouracil in the palliative treatment of patients with advanced metastatic colorectal
Categories: Compounds used in a research, industrial, or household settingSynonyms: N-[4-({[(6S)-2-amino-5-formyl-4-oxo-1,4,5,6,7,8-hexahydropteridin-6-yl]methyl}amino)benzoyl]-L-glutamic acidAbaloparatide
go.drugbank.com/drugs/DB05084ApprovedInvestigational[L740] In October 2022, the EMA's Committee for Medicinal Products for Human Use (CHMP) recommended abaloparatide be granted marketing authorization in Europe [L43552] and the drug was fully authorized … [L740] It was first approved by the FDA on April 28, 2017,[A256748] for the treatment of osteoporosis in postmenopausal women and is also used to increase bone density in men with osteoporosis.
Formestane
go.drugbank.com/drugs/DB08905ApprovedWithdrawnIt is not US FDA approved, and the intramuscular injection form of formestane (Lentaron) which was approved in Europe has been withdrawn. … Formestane was the first selective, type I, steroidal aromatase inhibitor used in the treatment of estrogen-receptor positive breast cancer in post-menopausal women.